Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Janssen
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase
The primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic pe...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures, Followed by an Open-Label Extension Study
STUDY 3013 To compare the efficacy safety, and tolerability of carisbamate as adjunctive treatment of partial onset seizures, relative to placebo, as measured by the: · Percent reduction in partial ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
An Effectiveness and Safety Study of Inhaled JNJ 49095397 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
The primary objective is to assess the efficacy (as measured by change from baseline in prebronchodilator [preBD] percent predicted FEV1) of JNJ-49095397 compared with placebo in subjects with sympto...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants with Previously Untreated Multiple Myeloma
Primary Objective : The primary objective is to compare the efficacy of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain
The primary objectives of this study are to evaluate the analgesic effect size over 12 weeks of several doses and dosage regimens of JNJ-42160443 compared with placebo in subjects with moderate to sev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Janssen-Cilag International NV
Update Il y a 4 ans
A study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus Estudio de los efectos de canagliflozina en los criterios de valoración renales en sujetos adultos con diabetes mellitus de tipo 2
1. To assess the effect of canagliflozin compared to placebo on progression of albuminuria. 1. Evaluar el efecto de la canagliflozina, en comparación con placebo, sobre la progresión de la album...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 4 ans
Étude CR103015 : Étude de phase 1b, visant à évaluer le daratumumab (JNJ-54767414 (Humax®CD38)) en association avec les traitements de référence, chez des patients présentant un myélome multiple. [essai clos aux inclusions]
L’objectif de cette étude est d’évaluer la sécurité d’emploi, la tolérance et la dose la mieux adaptée de daratumumab à administrer en combinaison avec différents traitements de fonds, chez des patien...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Janssen-Cilag International N.V
Update Il y a 6 ans
Étude CR102786 : Étude de phase 3, randomisé en double aveugle, évaluant l’efficacité l’ibrutinib contre placébo, en association avec soit avec une chimiothérapie BR (bendasmustine et rituximab), soit une chimiothérapie R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone), chez des patients ayant un lymphome non hodgkinien indolent antérieurement traité. [essai clos aux inclusions]
L’objectif de cette étude est de comparer l’efficacité d’un traitement associant l’ibrutinib à une chimiothérapie standard de type BR (bendasmustine et rituximab) ou de type R-CHOP (rituximab, cycloph...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Janssen-Cilag Medical Affairs EMEA
Update Il y a 4 ans
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day) compared w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Harry LA Janssen, MD PhD
Update Il y a 4 ans
Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study
Background and rationale Chronic hepatitis B is the most common cause of liver cirrhosis and hepatocellular carcinoma worldwide.(1) Antiviral therapy with oral nucleoside analogs and inter...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next